Blog

Archive for the ‘Volatility’ Category

Nektar’s plunge is a buying opportunity–so I’m adding more to my Volatility Portfolio

What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the company's NKTR-214 cancer drug receiving drugs that were less effective than […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

A fine volatility this is–just kind of strange

This post should be song to the tune of "A Fine Romance." (It helps if you can dance like Fred Astaire. Or sing like Ella.) "A fine romance, with no kisses A fine romance, my friend, this is We should be like a couple of hot tomatoes But you're as cold as yesterday's mashed potatoes […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Selling my Parsley Energy call options out of my Volatility Portfolio

Shares of Permian Basin oil shale producer Parsley Energy (PE) were up 16.45% as of 3 p.m. New York time this afternoon. The company reported second quarter earnings of 32 cents a share (after adjusting for a one-time tax-related gain). Unadjusted earnings came to 41 cents a share, down from 44 cents a share last […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Trump’s new round of China tariffs freaks out financial–especially bond–markets

So much for any hopes that the resumption of U.S-China trade talks would put an end to the tariff war in anything like the near term. The new round of talks only began on Wednesday, was adjourned after a day, and was scheduled to resume in Washington in September. This morning, though, President Donald Trump […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Selling Pro Shares Short Treasury ETF out of my Volatility Portfolio

I bought this position in the Pro Shares Short 7-10 Year Treasury ETF (TBX) in my Volatility Portfolio on February 2, 2018, back in the days when it looked like the Federal Reserve was firmly locked into a policy of interest rate increases. An interest rate increase pushes down the prices of existing bonds with […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Using softness to add more Treasury exposure to Volatility Portfolio

Treasury prices have been a little weak over the last two weeks. As a consequence the Vanguard Intermediate Term Treasury ETF (VGIT) and the Vanguard Short Term Treasury ETF (VGSH), for example, have dropped from highs on June 25 of $66.03 and $60.94, respectively, to $$65.56 and $60.75 at 3 .p.m New York time today. […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

July interest rate cut from Fed looks like done deal after Powell testimony

Federal Reserve chair Jerome Powell had an opportunity this morning to talk down the odds of an interest rate cut at the central bank's July 31 meeting in testimony in front of the House Financial Services Committee. He didn't--and I think that makes a 25 basis point cut from the Fed the end of July […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Sangamo gets RMAT status for its hemophilia gene therapy

On July 5 Sangamo Therapeutics (SGMO) and partner Pfizer (PFE) announced update results of a Phase 1/2 study of Sangamo's SB-525 gene therapy for severe hemophilia A. The companies also announced that the U.S. Food & Drug Administration had granted regenerative medicine advanced therapy (RMAT) designation to SB-525. RMAT status is given to therapies intended […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Head of Cleveland Fed argues against July interest rate cut–markets shrugs off her comments

In a speech today, July 2, in London Loretta Mester, president of the Cleveland Federal Reserve Bank, argued against an interest rate cut at the central bank's July 31 meeting. “Cutting rates at this juncture could reinforce negative sentiment about a deterioration in the outlook even if this is not the baseline view,” she said. A […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.

Bonus Dividend Pick for my Volatility Portfolio–DOW, a cash cow with a 5.5% yield

Today, June 28, I added Corteva (CTVA), one of the three stocks to emerge from the merger, reorganization, and then breakup of Dow and DuPont, to my Volatility Portfolio.  . On Monday,  I'll be adding another from that breakup to my Volatility Portfolio. This time it's Dow (DOW), the commodity chemicals vertical that resulted from […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.